Clinical trial registry record

Effects of Goji vs. Fiber on Macular Degeneration

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 17, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06237127
Last registry update
July 17, 2026
Status
Recruiting
Phase
Phase not reported
Sponsor
University of California, Davis
Enrollment
60
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
RANDOMIZED · PARALLEL · SUPPORTIVE CARE · NONE
Evidence population
Human clinical study registration
Participants
60
Population
ALL · 65 Years to 95 Years
Duration
2024-04-29 to 2027-12-31
Intervention
Goji berry; Fiber
Comparator
Fiber
Outcomes measured
Macular pigment optical volume (MPOV) — Day 0 and Day 180; Stool microbiome — Day 0 and Day 180; Spectral Domain-Ocular Coherence Tomography (SD-OCT) — Day 0 and Day 180; Fundus autofluorescence (FAF) — Day 0 and Day 180; Color Fundus Photography (CFP) — Day 0 and Day 180; Microperimetry testing — Day 0 and Day 180; Dark adaptometry — Day 0 and Day 180; Plasma microbial metabolites — Day 0 and Day 180; Plasma lutein and zeaxanthin — Day 0 and Day 180; Lipoprotein profile — Day 0 and Day 180; HDL particle characteristics — Day 0 and Day 180; Peripheral blood mononuclear cells (PBMC) gene expression changes — Day 0 and Day 180; Cognitive function — Day 0 and Day 180; Handgrip strength — Day 0 and Day 180
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON